Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $35.1429.

Several equities analysts recently weighed in on the stock. BTIG Research raised their price target on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Robert W. Baird lowered their price objective on Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating for the company in a research note on Thursday. Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Alto Neuroscience in a report on Thursday. JonesTrading cut their target price on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th.

Trending Headlines about Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: Several brokers reaffirmed buy/outperform views and high upside potential — HC Wainwright kept a Buy and a $50 price target (large upside vs. current price). Article Title
• Positive Sentiment: Chardan Capital reaffirmed a Buy with a $30 target, signaling continued analyst conviction despite the trial miss. Article Title
• Positive Sentiment: JonesTrading kept a Buy rating while trimming its target from $49 to $44 — still implying substantial upside from current levels. Article Title
• Positive Sentiment: Robert W. Baird cut its target to $38 but left an Outperform rating — another signal that some analysts view the selloff as a buying opportunity. Article Title
• Neutral Sentiment: Wedbush trimmed its target to $21 and moved to a Neutral rating, reflecting a more cautious stance but only a small target cut vs. price. Article Title
• Neutral Sentiment: Company fundamentals: recent quarter slightly beat EPS expectations, Alto has a market cap near $689M, high liquidity metrics (current/quick ratio ~15.7) and high beta (~2.0) — factors that increase volatility but limit near-term solvency concerns.
• Negative Sentiment: Trial failure: Alto’s schizophrenia study missed its primary endpoint; that clinical setback is the primary driver of selling pressure and re-pricing. Article Title
• Negative Sentiment: Market reaction/coverage: multiple headlines highlight a sharp drop and pre-market weakness after the study news, amplifying volatility and headline-driven flows. Article Title
• Negative Sentiment: Sentiment hit from coverage calling the result a “shocking miss,” which can accelerate short-term selling and make recovery dependent on management commentary, further data, or new catalysts. Article Title

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $21.57 on Tuesday. The firm has a market capitalization of $688.95 million, a PE ratio of -9.89 and a beta of 2.01. The firm has a fifty day simple moving average of $19.27 and a two-hundred day simple moving average of $14.88. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $25.17.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. Analysts forecast that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several institutional investors have recently made changes to their positions in ANRO. Torren Management LLC purchased a new stake in shares of Alto Neuroscience in the fourth quarter valued at about $62,000. Balyasny Asset Management L.P. purchased a new stake in Alto Neuroscience in the 4th quarter valued at about $198,000. OMERS ADMINISTRATION Corp bought a new position in shares of Alto Neuroscience during the 4th quarter worth approximately $221,000. Vanguard Personalized Indexing Management LLC boosted its stake in shares of Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after buying an additional 2,055 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Alto Neuroscience in the 4th quarter worth approximately $304,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.